{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 40,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 18,
  "notes": "The slide uses a Kaplan-Meier plot to demonstrate clinical efficacy and a list to show upcoming regulatory milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/24",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.048,
        "y": 0.758
      },
      "kind": "callout",
      "text": "Ultomiris, zero adjudicated relapses out to 73.5 weeks",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "32b7ca2c-1c4f-4192-923f-1aa74103d0d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.6,
        "x": 0.05,
        "y": 0.28
      },
      "kind": "chart",
      "text": "Kaplan-Meier plot of proportion relapse-free over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95572a58-06a0-41ce-b3a8-5f31583eeada",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.3,
        "x": 0.675,
        "y": 0.25
      },
      "kind": "list",
      "text": "Key upcoming news flow for 2022 and 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2db714c0-28cf-4c56-8ac1-abc9d0c041f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.93,
        "x": 0.035,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Median (range) follow-up was 73.5 (11.0–117.7) weeks (ravulizumab) and 36.0 (1.9–117.7) weeks (placebo) NMOSD = neuromyelitis optica spectrum disorder; CI = confidence interval; reg. = regulatory; NF1-PN = neurofibromatosis type 1; PN = plexiform neurofibromas; gMG = generalised myasthenia gravis; s.c. = subcutaneous; PNH = paroxysmal nocturnal haemoglobinuria; aHUS = atypical haemolytic uraemic syndrome; GBS = Guillain-Barré syndrome; EVH = extravascular haemolysis.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "617cdd37-6b7d-4231-9c6f-4593989b227e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.85,
        "x": 0.035,
        "y": 0.13
      },
      "kind": "title",
      "text": "Remarkable results from CHAMPION-NMO Phase III for Ultomiris in NMOSD",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f59ca90a-41cd-4671-aa72-6e296491c760",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.46,
        "x": 0.035,
        "y": 0.06
      },
      "kind": "title",
      "text": "Rare Disease: R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ccdcc0f3-473a-4dc8-91f0-7b287998af77",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "dcd7ae5f-8070-470b-acd5-fc905d4687a4",
      "evidence": "chart/line: Kaplan-Meier plot of proportion relapse-free over time",
      "confidence": 0.7
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "1aa8b5a9-5820-4ba6-ba0f-4aad5cb58fd6",
      "evidence": "list/bullet: Key upcoming news flow for 2022 and 2023",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}